By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – A trio of Vermillion shareholders have notified the firm that they intend to nominate two people for election to the board of directors as they seek to replace Gail Page and John Hamilton.

Page is Vermillion's president and CEO, and Hamilton is a former VP and CFO of Depomed but is not an executive of the firm.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.